Regulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activities

Nature Communications

Volumn 6, Issue , 2015, Pages

  Kollareddy, Madhusudhan ^a   Dimitrova, Elizabeth ^b   Vallabhaneni, Krishna C ^a   Chan, Adriano ^c   Le, Thuc ^b   Chauhan, Krishna M ^a   Carrero, Zunamys I ^a   Ramakrishnan, Gopalakrishnan ^a   Watabe, Kounosuke ^d,g   Haupt, Ygal ^e,f   Haupt, Sue ^e,f   Pochampally, Radhika ^a   Boss, Gerard R ^c   Romero, Damian G ^a   Radu, Caius G ^b   Martinez, Luis A ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYCYTIDINE KINASE; GUANOSINE; GUANOSINE TRIPHOSPHATE; MUTANT PROTEIN; NUCLEOSIDE; NUCLEOTIDE; PROTEIN P53; TP53 PROTEIN, HUMAN;

CANCER; CELLS AND CELL COMPONENTS; ENZYME ACTIVITY; GENE EXPRESSION; METABOLISM; NUCLEIC ACID; PHENOTYPE; PROTEIN; TUMOR;

ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER PROGNOSIS; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; GAIN OF FUNCTION MUTATION; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; METABOLIC REGULATION; NUCLEOTIDE METABOLISM; PHENOTYPE; PROMOTER REGION; ANIMAL; BRAIN TUMOR; BREAST TUMOR; CANCER TRANSPLANTATION; CELL CYCLE; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; IMMUNOPRECIPITATION; KAPLAN MEIER METHOD; METABOLISM; MOUSE; MUTATION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SECONDARY; TUMOR CELL LINE; TUMOR INVASION; TUMOR STEM CELL ASSAY; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BRAIN NEOPLASMS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE KINASE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GUANOSINE TRIPHOSPHATE; HUMANS; IMMUNOPRECIPITATION; KAPLAN-MEIER ESTIMATE; MICE; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; NUCLEOSIDES; NUCLEOTIDES; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; TUMOR STEM CELL ASSAY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84935901131     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms8389     Document Type: Article

References (63)

1. Matoba, S. et al. p53 regulates mitochondrial respiration. Science 312, 1650-1653 (2006).
2. Bensaad, K. et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126, 107-120 (2006).
3. Jiang, P. et al. p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat. Cell Biol. 13, 310-316 (2011).
4. Zhang, C. et al. Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect. Proc. Natl Acad. Sci. USA 108, 16259-16264 (2011).
5. Levine, A. J., Feng, Z., Mak, T. W., You, H. & Jin, S. Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev. 20, 267-275 (2006).
6. Hu, W. et al. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc. Natl Acad. Sci. USA 107, 7455-7460 (2010).
7. Suzuki, S. et al. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc. Natl Acad. Sci. USA 107, 7461-7466 (2011).
8. Assaily, W. et al. ROS-mediated p53 induction of Lpin1 regulates fatty acid oxidation in response to nutritional stress. Mol. Cell 44, 491-501 (2011).
9. Buzzai, M. et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 67, 6745-6752 (2007).
10. Budanov, A. V., Sablina, A. A., Feinstein, E., Koonin, E. V. & Chumakov, P. M. Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD. Science 304, 596-600 (2004).
11. Sablina, A. A. et al. The antioxidant function of the p53 tumor suppressor. Nat. Med. 11, 1306-1313 (2005).
12. Yoon, K. A., Nakamura, Y. & Arakawa, H. Identification of ALDH4 as a p53-inducible gene and its protective role in cellular stresses. J. Hum. Genet. 49, 134-140 (2004).
13. Tan, M. et al. Transcriptional activation of the human glutathione peroxidase promoter by p53. J. Biol. Chem. 274, 12061-12066 (1999).
14. Wang, S. J. et al. p53-Dependent regulation of metabolic function through transcriptional activation of pantothenate kinase-1 gene. Cell Cycle 12, 753-761 (2013).
15. Muller, P. A. & Vousden, K. H. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell 25, 304-317 (2014).
16. Xiong, S. et al. Pla2g16 phospholipase mediates gain-of-function activities of mutant p53. Proc. Natl Acad. Sci. USA 111, 11145-11150 (2014).
17. Do, P. M. et al. Mutant p53 cooperates with ETS2 to promote etoposide resistance. Genes Dev. 26, 830-845 (2012).
18. Girardini, J. E. et al. A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell 20, 79-91 (2011).
19. Freed-Pastor, W. A. et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 148, 244-258 (2012).
20. Sampath, J. et al. Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. J. Biol. Chem. 276, 39359-39367 (2001).
21. Di Agostino, S. et al. Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 10, 191-202 (2006).
22. Stambolsky, P. et al. Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell 17, 273-285 (2010).
23. Li, D., Yallowitz, A., Ozog, L. & Marchenko, N. A gain-of-function mutant p53-HSF1 feed forward circuit governs adaptation of cancer cells to proteotoxic stress. Cell Death Dis. 5, e1194 (2014).
24. Kalo, E. et al. Mutant p53R273H attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high levels of reactive oxygen species. J. Cell Sci. 125, 5578-5586 (2012).
25. Zhang, C. et al. Tumour-associated mutant p53 drives the Warburg effect. Nat. Commun. 4, 2935 (2013).
26. Chavez-Perez, V. A., Strasberg-Rieber, M. & Rieber, M. Metabolic utilization of exogenous pyruvate by mutant p53 (R175H) human melanoma cells promotes survival under glucose depletion. Cancer Biol. Ther. 12, 647-656 (2011).
27. Liu, Y. C. et al. Global regulation of nucleotide biosynthetic genes by c-Myc. PLoS ONE 3, e2722 (2008).
28. Cunningham, J. T., Moreno, M. V., Lodi, A., Ronen, S. M. & Ruggero, D. Protein and nucleotide biosynthesis are coupled by a single rate-limiting enzyme, PRPS2, to drive cancer. Cell 157, 1088-1103 (2014).
29. Mannava, S. et al. Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells. Cell Cycle 7, 2392-2400 (2008).
30. Angus, S. P. et al. Retinoblastoma tumor suppressor targets dNTP metabolism to regulate DNA replication. J. Biol. Chem. 277, 44376-44384 (2002).
31. Wawrzyniak, J. A. et al. A purine nucleotide biosynthesis enzyme guanosine monophosphate reductase is a suppressor of melanoma invasion. Cell Rep. 5, 493-507 (2013).
32. Nakano, K., Balint, E., Ashcroft, M. & Vousden, K. H. A ribonucleotide reductase gene is a transcriptional target of p53 and p73. Oncogene 19, 4283-4289 (2000).
33. Tanaka, H. et al. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 404, 42-49 (2000).
34. Mondin, M. et al. Alterations in cytoskeletal protein expression by mycophenolic acid in human mesangial cells requires Rac inactivation. Biochem. Pharmacol. 73, 1491-1498 (2007).
35. Ji, Y., Gu, J., Makhov, A. M., Griffith, J. D. & Mitchell, B. S. Regulation of the interaction of inosine monophosphate dehydrogenase with mycophenolic Acid by GTP. J. Biol. Chem. 281, 206-212 (2006).
36. Kang, Y. et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3, 537-549 (2003).
37. Bos, P. D. et al. Genes that mediate breast cancer metastasis to the brain. Nature 459, 1005-1009 (2009).
38. Bergman, A. M., Pinedo, H. M. & Peters, G. J. Determinants of resistance to 2', 2'-difluorodeoxycytidine (gemcitabine). Drug Resist Updat. 5, 19-33 (2002).
39. Geutjes, E. J., Tian, S., Roepman, P. & Bernards, R. Deoxycytidine kinase is overexpressed in poor outcome breast cancer and determines responsiveness to nucleoside analogs. Breast Cancer Res. Treat. 131, 809-818 (2012).
40. Saiki, Y. et al. DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells. Biochem. Biophys. Res. Commun. 421, 98-104 (2012).
41. Braas, D. et al. Metabolomics strategy reveals subpopulation of liposarcomas sensitive to gemcitabine treatment. Cancer Discov. 2, 1109-1117 (2012).
42. Choi, O. et al. A deficiency in nucleoside salvage impairs murine lymphocyte development, homeostasis, and survival. J. Immunol. 188, 3920-3927 (2012).
43. Austin, W. R. et al. Nucleoside salvage pathway kinases regulate hematopoiesis by linking nucleotide metabolism with replication stress. J. Exp. Med. 209, 2215-2228 (2012).
44. Nathanson, D. A. et al. Co-targeting of convergent nucleotide biosynthetic pathways for leukemia eradication. J. Exp. Med. 211, 473-486 (2014).
45. Bjursell, G. & Reichard, P. Effects of thymidine on deoxyribonucleoside triphosphate pools and deoxyribonucleic acid synthesis in Chinese hamster ovary cells. J. Biol. Chem. 248, 3904-3909 (1973).
46. Larsson, K. M. et al. Structural mechanism of allosteric substrate specificity regulation in a ribonucleotide reductase. Nat. Struct. Mol. Biol. 11, 1142-1149 (2004).
47. van de Vijver, M. J. et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009 (2002).
48. Furuta, E., Okuda, H., Kobayashi, A. & Watabe, K. Metabolic genes in cancer: their roles in tumor progression and clinical implications. Biochim. Biophys. Acta 1805, 141-152 (2010).
49. Hanel, W. et al. Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis. Cell Death Differ. 20, 898-909 (2013).
50. Lang, G. A. et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119, 861-872 (2004).
51. Olive, K. P. et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119, 847-860 (2004).
52. Liu, D. P., Song, H. & Xu, Y. A common gain of function of p53 cancer mutants in inducing genetic instability. Oncogene 29, 949-956 (2010).
53. Song, H., Hollstein, M. & Xu, Y. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat. Cell Biol. 9, 573-580 (2007).
54. Lee, M. K. et al. Cell-type, dose, and mutation-type specificity dictate mutant p53 functions in vivo. Cancer Cell 22, 751-764 (2012).
55. Marin, M. C. et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat. Genet. 25, 47-54 (2000).
56. Bergamaschi, D. et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3, 387-402 (2003).
57. Coffill, C. R. et al. Mutant p53 interactome identifies nardilysin as a p53R273H-specific binding partner that promotes invasion. EMBO Rep. 13, 638-644 (2012).
58. Xu, J. et al. Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat. Chem. Biol. 7, 285-295 (2011).
59. Freed-Pastor, W. A. & Prives, C. Mutant p53: one name, many proteins. Genes Dev. 26, 1268-1286 (2012).
60. Egawa, K. et al. Membrane-targeted phosphatidylinositol 3-kinase mimics insulin actions and induces a state of cellular insulin resistance. J. Biol. Chem. 274, 14306-14314 (1999).
61. Guedj, M. et al. A refined molecular taxonomy of breast cancer. Oncogene 31, 1196-1206 (2012).
62. Irizarry, R. A. et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4, 249-264 (2003).
63. Gyorffy, B. et al. An online survival analysis tool to rapidly assess the effect of 22, 277 genes on breast cancer prognosis using microarray data of 1, 809 patients. Breast Cancer Res. Treat. 123, 725-731 (2010).